Journal of Clinical Oncology, Vol 8, 689-704, Copyright © 1990 by American Society of Clinical Oncology

ARTICLES

Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood

HS Chan, PS Thorner, G Haddad and V Ling
Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.

Increased expression of P-glycoprotein is associated with multidrug resistance (MDR) in many cell lines. Significant levels of P- glycoprotein have been detected in a number of human tumors. The purpose of this study was to determine whether P-glycoprotein expression correlates with both response to chemotherapy and prognosis in soft tissue sarcoma of childhood. In a retrospective study, biopsy samples from 30 cases of rhabdomyosarcoma (RMS) and undifferentiated sarcoma (US) treated at The Hospital for Sick Children in Toronto were analyzed using a semiquantitative immunohistochemical procedure. P- glycoprotein was detected in nine patients, four at diagnosis, and five at subsequent biopsy. All nine patients relapsed after a clinical response (complete [CR] 55%, partial [PR] 45%) to chemotherapy. Twenty of 21 patients with consistently P-glycoprotein-negative tumors received chemotherapy and they all responded clinically (CR 80%, PR 20%). Only one of these 20 patients has relapsed. The probability of relapse-free survival was significantly different (P less than .000000012) in chemotherapy-treated patients whose tumors contained detectable levels of P-glycoprotein (n = 9), compared with those whose tumors contained no detectable P-glycoprotein (n = 20). The overall probability of survival was also significantly different in these two groups (P less than .0000267). Both relapse-free and overall survivals remained statistically different in the two groups of patients when analyzed by the log-rank method, after adjustment for differences in stages and sites. The incidence of other adverse prognostic factors in the two groups, for example, younger and older ages, low pretreatment lymphocyte counts, large tumors, and unfavorable histology were not significantly different. Thus, detectable P-glycoprotein appears to be an important adverse prognostic factor in children with soft tissue sarcoma, and consistent absence of the protein is associated with a favorable prognosis.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. P. S. Filho, Z. M. S. Correa, A. N. Odashiro, A. B. Coutinho, M. C. Martins, C. M. Erwenne, and M. N. Burnier Jr Histopathological Features and P-glycoprotein Expression in Retinoblastoma Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3478 - 3483. [Abstract] [Full Text] [PDF]

				K. E. Miletti-Gonzalez, S. Chen, N. Muthukumaran, G. N. Saglimbeni, X. Wu, J. Yang, K. Apolito, W. J. Shih, W. N. Hait, and L. Rodriguez-Rodriguez The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer Cancer Res., August 1, 2005; 65(15): 6660 - 6667. [Abstract] [Full Text] [PDF]

				J.-M. Yang, Z. Xu, H. Wu, H. Zhu, X. Wu, and W. N. Hait Overexpression of Extracellular Matrix Metalloproteinase Inducer in Multidrug Resistant Cancer Cells Mol. Cancer Res., April 1, 2003; 1(6): 420 - 427. [Abstract] [Full Text] [PDF]

				U. Stein, K. Jurchott, M. Schlafke, and P. Hohenberger Expression of Multidrug Resistance Genes MVP, MDR1, and MRP1 Determined Sequentially Before, During, and After Hyperthermic Isolated Limb Perfusion of Soft Tissue Sarcoma and Melanoma Patients J. Clin. Oncol., August 1, 2002; 20(15): 3282 - 3292. [Abstract] [Full Text] [PDF]

				K. L. Mealey, R. Barhoumi, R. C. Burghardt, S. Safe, and D. T. Kochevar Doxycycline Induces Expression of P Glycoprotein in MCF-7 Breast Carcinoma Cells Antimicrob. Agents Chemother., March 1, 2002; 46(3): 755 - 761. [Abstract] [Full Text] [PDF]

				H. A. Cocker, N. Tiffin, K. Pritchard-Jones, C. R. Pinkerton, and L. R. Kelland In Vitro Prevention of the Emergence of Multidrug Resistance in a Pediatric Rhabdomyosarcoma Cell Line Clin. Cancer Res., October 1, 2001; 7(10): 3193 - 3198. [Abstract] [Full Text] [PDF]

				R. Advani, G. A. Fisher, B. L. Lum, J. Hausdorff, J. Halsey, M. Litchman, and B. I. Sikic A Phase I Trial of Doxorubicin, Paclitaxel, and Valspodar (PSC 833), a Modulator of Multidrug Resistance Clin. Cancer Res., May 1, 2001; 7(5): 1221 - 1229. [Abstract] [Full Text]

				J. Albertus and R. Laine Enhanced xenobiotic transporter expression in normal teleost hepatocytes: response to environmental and chemotherapeutic toxins J. Exp. Biol., January 1, 2001; 204(2): 217 - 227. [Abstract] [PDF]

				B. E. C. Plaat, H. Hollema, W. M. Molenaar, G. H. T. Broers, J. Pijpe, M. F. Mastik, H. J. Hoekstra, E. van den Berg, R. J. Scheper, and W. T. A. van der Graaf Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins J. Clin. Oncol., September 18, 2000; 18(18): 3211 - 3220. [Abstract] [Full Text] [PDF]

				J. S. Wunder, S. B. Bull, V. Aneliunas, P. D. Lee, A. M. Davis, C. P. Beauchamp, E. U. Conrad, R. J. Grimer, J. H. Healey, M. J. Rock, et al. MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study J. Clin. Oncol., July 14, 2000; 18(14): 2685 - 2694. [Abstract] [Full Text] [PDF]

				A. Abolhoda, A. E. Wilson, H. Ross, P. V. Danenberg, M. Burt, and K. W. Scotto Rapid Activation of MDR1 Gene Expression in Human Metastatic Sarcoma after in Vivo Exposure to Doxorubicin Clin. Cancer Res., November 1, 1999; 5(11): 3352 - 3356. [Abstract] [Full Text] [PDF]

				T. D. PEABODY, C. P. GIBBS, and M. A. SIMON Current Concepts Review - Evaluation and Staging of Musculoskeletal Neoplasms J. Bone Joint Surg. Am., August 1, 1998; 80(8): 1204 - 18. [Full Text]

				A. Lau, S. Nightingale, G. P. Taylor, T. W. Gant, and A. J. Cann Enhanced MDR1 Gene Expression in Human T-Cell Leukemia Virus-I-Infected Patients Offers New Prospects for Therapy Blood, April 1, 1998; 91(7): 2467 - 2474. [Abstract] [Full Text] [PDF]

				G. Chen, G. E. Duran, K. A. Steger, N. J. Lacayo, J.-P. Jaffrezou, C. Dumontet, and B. I. Sikic Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins J. Biol. Chem., February 28, 1997; 272(9): 5974 - 5982. [Abstract] [Full Text] [PDF]

				B. L. Gallie, A. Budning, G. DeBoer, J. J. Thiessen, G. Koren, Z. Verjee, V. Ling, and H. S. L. Chan Chemotherapy With Focal Therapy Can Cure Intraocular Retinoblastoma Without Radiotherapy Arch Ophthalmol, November 1, 1996; 114(11): 1321 - 1328. [Abstract] [PDF]

				C. Duhem, F. Ries, and M. Dicato What does Multidrug Resistance (MDR) Expression Mean in the Clinic? Oncologist, June 1, 1996; 1(3): 151 - 158. [Abstract] [Full Text] [PDF]

				H. TAKESHITA, M. C. GEBHARDT, D. S. SPRINGFIELD, K. KUSUZAKI, and H. J. MANKIN Experimental Models for the Study of Drug Resistance in Osteosarcoma: P-Glycoprotein-Positive, Murine Osteosarcoma Cell Lines J. Bone Joint Surg. Am., March 1, 1996; 78(3): 366 - 75. [Abstract] [Full Text]

				N. Baldini, K. Scotlandi, G. Barbanti-Brodano, M. C. Manara, D. Maurici, G. Bacci, F. Bertoni, P. Picci, S. Sottili, M. Campanacci, et al. Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome N. Engl. J. Med., November 23, 1995; 333(21): 1380 - 1385. [Abstract] [Full Text] [PDF]

				D R Ferry and D J Kerr Multidrug resistance in cancer BMJ, January 15, 1994; 308(6922): 148 - 149. [Full Text]

				C.H. Lee, G. Bradley, and V. Ling Expression of P-Glycoprotein in Normal and Malignant Rat Liver Cells Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 607 - 615. [Abstract] [PDF]

				D. J. Kelley, Z. P. Pavelic, M. Gapany, P. Stambrook, L. Pavelic, S. Gapany, and J. L. Gluckman Detection of P-Glycoprotein in Squamous Cell Carcinomas of the Head and Neck Arch Otolaryngol Head Neck Surg, April 1, 1993; 119(4): 411 - 414. [Abstract] [PDF]